Revolution Medicines, Inc. provided earnings guidance for the full year 2022. For the period, the company projected GAAP net loss to be between $260 million and $280 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.02 USD | -2.11% | -1.91% | +36.05% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.05% | 6.44B | |
+49.21% | 56.87B | |
+36.39% | 39.72B | |
-6.86% | 39.27B | |
-4.42% | 28.73B | |
+12.00% | 26.21B | |
-18.27% | 19.79B | |
+29.57% | 12.28B | |
+25.41% | 12.23B | |
-0.35% | 12.12B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Provides Earnings Guidance for the Full Year 2022